Sinopharm's COVID-19 vaccine production capacity to exceed 1 billion in 2021
China National Pharmaceutical Group's (Sinopharm) production capacity for inactivated COVID-19 vaccines will exceed one billion doses in 2021, accoring to Sinopharm's Chairman Liu Jingzhen.
Sinopharm has gained attention for its achievements in the battle against COVID-19. It developed nucleic acid test kits within 48 hours, and successfully prepared plasma for COVID-19 patients in severe situations.
It took only 335 days from developing an inactivated vaccine to obtaining the conditional marketing authorization. Up to now, more than 43 million doses of inactivated Sinopharm vaccines have been used worldwide.